PT935607E - Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes - Google Patents

Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes

Info

Publication number
PT935607E
PT935607E PT97938386T PT97938386T PT935607E PT 935607 E PT935607 E PT 935607E PT 97938386 T PT97938386 T PT 97938386T PT 97938386 T PT97938386 T PT 97938386T PT 935607 E PT935607 E PT 935607E
Authority
PT
Portugal
Prior art keywords
proteins
physius
monumental
class
multivalent soluble
Prior art date
Application number
PT97938386T
Other languages
English (en)
Inventor
Jack L Strominger
Kai W Wucherpfennig
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of PT935607E publication Critical patent/PT935607E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97938386T 1996-08-16 1997-08-15 Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes PT935607E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2407796P 1996-08-16 1996-08-16

Publications (1)

Publication Number Publication Date
PT935607E true PT935607E (pt) 2004-12-31

Family

ID=21818743

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97938386T PT935607E (pt) 1996-08-16 1997-08-15 Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes

Country Status (11)

Country Link
EP (1) EP0935607B1 (pt)
JP (1) JP2000516470A (pt)
AT (1) ATE272070T1 (pt)
AU (1) AU730457B2 (pt)
CA (1) CA2263195A1 (pt)
DE (1) DE69730038T2 (pt)
DK (1) DK0935607T3 (pt)
ES (1) ES2221065T3 (pt)
NZ (1) NZ333915A (pt)
PT (1) PT935607E (pt)
WO (1) WO1998006749A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
NZ506071A (en) * 1998-02-19 2003-05-30 Harvard College Monovalent, multivalent, and multimeric major histocompatibility complex (MHC) binding domain fusion proteins and conjugates, and uses therefore
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
WO2002062846A2 (en) * 1999-12-17 2002-08-15 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of antigens and uses thereof
DE60138922D1 (de) 2000-10-10 2009-07-16 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
WO2002080963A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP1400534B1 (en) * 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
JP6364352B2 (ja) * 2012-01-06 2018-07-25 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
WO2015051330A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3155426B1 (en) 2014-06-13 2023-07-19 Immudex ApS General detection and isolation of specific cells by binding of labeled molecules
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
JP7194020B2 (ja) 2015-10-22 2022-12-21 ジュノ セラピューティクス ゲーエムベーハー 細胞の培養方法ならびにそのためのキットおよび装置
MX2019005497A (es) * 2016-11-09 2019-11-18 Uti Lp Moleculas de pmhc de clase ii recombinantes.
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership Methods of treating autoimmune disease
US20220275043A1 (en) * 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
US20240190941A1 (en) * 2021-04-07 2024-06-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
JPH10503379A (ja) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド Ｍｈｃ複合体およびその用途

Also Published As

Publication number Publication date
EP0935607A2 (en) 1999-08-18
WO1998006749A2 (en) 1998-02-19
ATE272070T1 (de) 2004-08-15
DE69730038D1 (de) 2004-09-02
JP2000516470A (ja) 2000-12-12
DE69730038T2 (de) 2004-11-25
ES2221065T3 (es) 2004-12-16
CA2263195A1 (en) 1998-02-19
WO1998006749A3 (en) 1998-06-11
NZ333915A (en) 2000-11-24
DK0935607T3 (da) 2004-12-06
AU730457B2 (en) 2001-03-08
AU4072397A (en) 1998-03-06
EP0935607B1 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
PT935607E (pt) Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes
DE69933216D1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP0832105A4 (en) IMMUNOGENIC PEPTIDES OF PROSTATE-SPECIFIC ANTIGENS
MA24638A1 (fr) Vaccin
NL300106I2 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
DE69837283D1 (de) Verwendung von einem phospatidylserine/polypeptide konjugat um autoimmunität hervorzurufen in der behandlung von krebs
FI895382A0 (fi) Uretan-skyddade aminosyra-n -karboxianhydrider.
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
CA2045869A1 (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
EA200000311A1 (ru) Новый белок иммунной системы - кау
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
EA199901013A1 (ru) Гели пролонгированного действия
BG102362A (en) New derivatives of amino acids, their preparation and application
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
BR0110577A (pt) Decorina transgenicamente produzida
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
GB9501826D0 (en) Polypeptide fragments
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
EP1136555A4 (en) TUMORANT PROTEIN ART-1 AND TUMORANT PEPTIDES THEREOF